Topic

Articles

The government is exploring terms by which the UK could still be part of EMA after its departure from the EU, Theresa May said in a key speech on Brexit.

Prime Minister Wants UK to Remain Part of EMA After Brexit

The agency is sending a survey out to pharmaceutical companies in the UK to gain information on their preparedness for Brexit.

EMA Wants to Know if Pharma is Ready for Brexit

The agency and the European Commission published updated guidance to answer questions about Brexit.

EMA Updates Brexit Guidance

Following a vote by member states in favor of Amsterdam as the agency’s new headquarters, the relocation will take place over the next 16 months, with operations expected to start up in March 2019.

EMA to Relocate to New HQ in Amsterdam in Wake of Brexit

The agency has published a continuity plan for its move from the United Kingdom.


EMA Publishes Brexit Plan

The agency has developed a business continuity plan to ensure that the public’s health is protected during the agency’s relocation.


EMA Unveils Brexit Plan

The agency’s management board discussed plans for the relocation of EMA at its June 2017 meeting.


EMA Progresses on Brexit Plans

Sean Milmo is a freelance writer based in Essex, UK.

The impact of Brexit on the European drug approval regulatory framework presents challenges for EMA.

EMA Faces Brexit Challenges

The agency released guidance for industry regarding the United Kingdom’s withdrawal from the European Union.


EMA Issues Brexit Guidance

On April 28, 2017, the European Medicines Agency announced that it met with members of the heads of the National Competent Authorities (NCAs) of the member states of the European Union to discuss the United Kingdom’s exit from the EU (Brexit) and how the agency and the member states will handle the evaluation and monitoring of drugs going forward.

Bio/Pharma and Brexit